“Our Experiences With Erlotinib in Second and Third Line Treatment Patients With Advanced Stage Iiib Iv Non-Small Cell Lung Cancer”. 2008. Biomolecules and Biomedicine 8 (4): 386-90. https://doi.org/10.17305/bjbms.2008.2905.